Dongmei Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Dongmei Li has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Wenxing He
Breast Cancer Center, Jiangxi Cancer Hospital (The Second Affiliated Hospital of Nanchang Medical College), Nanchang, China
2 shared publicationsHaoyi Zhang
School of Public Health, Nanchang University, Nanchang, China
1 shared publicationHong Cheng
Breast Cancer Center, Jiangxi Cancer Hospital of Nanchang Medical College, Nanchang, People’s Republic of China
1 shared publicationJianfeng Wen
Hospital 908 of the Joint Support Force of the Chinese People’s Liberation Army, Nanchang, China
1 shared publication- Tenghua Yu
Breast Cancer Center, Jiangxi Cancer Hospital (The Second Affiliated Hospital of Nanchang Medical College), Nanchang, China
1 shared publication - Wenxing He
Breast Cancer Center,Jiangxi Cancer Hospital of Nanchang University;Jiangxi Key Laboratory of Translational Research for Cancer,No. 519 East Beijing Road, Nanchang, Jiangxi, 330029, China
1 shared publication
Latest Publications
- Open Access
- 20 November 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1675874
Significance of SUMOylation in breast cancer progression: a comprehensive investigation using single-cell analysis and bioinformatics
Background: Breast cancer remains a major global health challenge because of limitations in early detection and therapeutic outcomes. This study employed bulk and single-cell RNA sequencing to investigate SUMOylation-associated molecular networks, aiming to identify prognostic biomarkers and potential therapeutic applications. Methods: Transcriptomic profiling was performed on 1,445 breast cancer and 113 normal samples to identify differentially expressed genes. Four hub genes, NR3C2 , CDCA8 , AURKA , and PLK1 , were prioritized using machine learning. Consensus clustering stratified patients into molecular subtypes based on the hub gene expression patterns. Differential immune infiltration analysis was used to evaluate 28 immune cell populations between the subtypes. Hub gene-immune cell interactions were visualized using bubble diagrams. Pharmacogenomic sensitivity profiling was performed using subtype-specific drug response data. Single-cell sequencing identified epithelial subclusters enriched for hub genes, and transcription factor networks were analyzed using SCENIC. Pan-cancer validation was performed to assess the oncogenic role of hub genes in 21 malignancies. Statistical significance was determined using the Student’s t -test ( p < 0.0001). Results: Tumor tissues exhibited significant upregulation of CDCA8 , AURKA , and PLK1 , whereas NR3C2 was notably downregulated ( p < 0.0001). Consensus clustering identified two distinct molecular subtypes: Subtype1, characterized by NR3C2 upregulation and poorer prognosis, and Subtype2, distinguished by enhanced expression of CDCA8 , AURKA , and PLK1 , correlating with favorable outcomes. Notably, PIK3CA mutations were prevalent in Subtype1, whereas TP53 mutations dominated Subtype2. Immune infiltration profiles differed significantly between the two subtypes for most immune cell types. Pharmacogenomic assessments revealed distinct drug sensitivity profiles for each subtype in response to various therapeutic agents. A pan-cancer analysis of the four hub genes demonstrated consistent expression patterns, immune correlations, and prognostic associations across malignancies. Conclusion: Our findings reveal that SUMOylation subtypes in breast cancer exhibit distinct prognostic, immunological and pharmacogenomic profiles. These insights may provide candidate biomarkers for future personalized treatment strategies for breast cancer and potentially for other malignancies.
- 20 November 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1675874
Open AccessSignificance of SUMOylation in breast cancer progression: a comprehensive investigation using single-cell analysis and bioinformatics
Background: Breast cancer remains a major global health challenge because of limitations in early detection and therapeutic outcomes. This study employed bulk and single-cell RNA sequencing to investigate SUMOylation-associated molecular networks, aiming to identify prognostic biomarkers and potential therapeutic applications. Methods: Transcriptomic profiling was performed on 1,445 breast cancer and 113 normal samples to identify differentially expressed genes. Four hub genes, NR3C2 , CDCA8 , AURKA , and PLK1 , were prioritized using machine learning. Consensus clustering stratified patients into molecular subtypes based on the hub gene expression patterns. Differential immune infiltration analysis was used to evaluate 28 immune cell populations between the subtypes. Hub gene-immune cell interactions were visualized using bubble diagrams. Pharmacogenomic sensitivity profiling was performed using subtype-specific drug response data. Single-cell sequencing identified epithelial subclusters enriched for hub genes, and transcription factor networks were analyzed using SCENIC. Pan-cancer validation was performed to assess the oncogenic role of hub genes in 21 malignancies. Statistical significance was determined using the Student’s t -test ( p < 0.0001). Results: Tumor tissues exhibited significant upregulation of CDCA8 , AURKA , and PLK1 , whereas NR3C2 was notably downregulated ( p < 0.0001). Consensus clustering identified two distinct molecular subtypes: Subtype1, characterized by NR3C2 upregulation and poorer prognosis, and Subtype2, distinguished by enhanced expression of CDCA8 , AURKA , and PLK1 , correlating with favorable outcomes. Notably, PIK3CA mutations were prevalent in Subtype1, whereas TP53 mutations dominated Subtype2. Immune infiltration profiles differed significantly between the two subtypes for most immune cell types. Pharmacogenomic assessments revealed distinct drug sensitivity profiles for each subtype in response to various therapeutic agents. A pan-cancer analysis of the four hub genes demonstrated consistent expression patterns, immune correlations, and prognostic associations across malignancies. Conclusion: Our findings reveal that SUMOylation subtypes in breast cancer exhibit distinct prognostic, immunological and pharmacogenomic profiles. These insights may provide candidate biomarkers for future personalized treatment strategies for breast cancer and potentially for other malignancies.
- Open Access
- 20 October 2023
- Published by Springer Nature in Discover Oncology
- Vol. 14 (1) , 1-20
PIK3CD correlates with prognosis, epithelial–mesenchymal transition and tumor immune infiltration in breast carcinoma
Background: Breast carcinoma (BRCA) is one of the most common, fatal, and aggressive cancers, with increasing morbidity that has a major impact on human health. PIK3CD appears to have important roles in the beginning and advancement of various forms of human cancer, according to mounting data. However,the particular role and mechanism of PIK3CD in BRCA remains not fully identified. Methodology: The Cancer Genome Atlas (TCGA, https://portal.gdc.cancer.gov/), Genotype-Tissue Expression (GTEx) data and the UCSC Xena browser (https://xenabrowser.net) data were used in this study’s initial pan-cancer analysis of PIK3CD expression and prognosis. Circular RNAs (circRNAs) that regulated the expression of PIK3CD were subsequently found using a combination of in silico investigations of expression, correlation, and survival. Measurements of PIK3CD expression and an analysis of the in vitro function of PIK3CD in BRCA cells were performed using real-time RT-PCR, Western blotting and Transwell assays. Results: In BRCA GLI2, RAB32, LAMB1, MGAT2, ITGA8, CHF, COL6A3 and PRRX1-miR-30b-5p axis was identified as the most likely upstream CircRNA-related route of PIK3CD. PIK3CD was correlated with the expression of EMT markers. The PIK3CD cDNA improved the capacity for invasion and migration. The expression of PIK3CD was linked to some of the m1A/m5C/m6A regulators. Additionally, it was discovered that the expression of PIK3CD was found to be highly connected to the expression of immunological checkpoints, immune cell biomarkers, and tumor immune cell invasion. Conclusions: Our findings reveal that PIK3CD expression is associated with prognosis, EMT, and tumor immune infiltration in BRCA patients.
- 20 October 2023
- Published by Springer Nature in Discover Oncology
- Vol. 14 (1) , 1-20
Open AccessPIK3CD correlates with prognosis, epithelial–mesenchymal transition and tumor immune infiltration in breast carcinoma
Background: Breast carcinoma (BRCA) is one of the most common, fatal, and aggressive cancers, with increasing morbidity that has a major impact on human health. PIK3CD appears to have important roles in the beginning and advancement of various forms of human cancer, according to mounting data. However,the particular role and mechanism of PIK3CD in BRCA remains not fully identified. Methodology: The Cancer Genome Atlas (TCGA, https://portal.gdc.cancer.gov/), Genotype-Tissue Expression (GTEx) data and the UCSC Xena browser (https://xenabrowser.net) data were used in this study’s initial pan-cancer analysis of PIK3CD expression and prognosis. Circular RNAs (circRNAs) that regulated the expression of PIK3CD were subsequently found using a combination of in silico investigations of expression, correlation, and survival. Measurements of PIK3CD expression and an analysis of the in vitro function of PIK3CD in BRCA cells were performed using real-time RT-PCR, Western blotting and Transwell assays. Results: In BRCA GLI2, RAB32, LAMB1, MGAT2, ITGA8, CHF, COL6A3 and PRRX1-miR-30b-5p axis was identified as the most likely upstream CircRNA-related route of PIK3CD. PIK3CD was correlated with the expression of EMT markers. The PIK3CD cDNA improved the capacity for invasion and migration. The expression of PIK3CD was linked to some of the m1A/m5C/m6A regulators. Additionally, it was discovered that the expression of PIK3CD was found to be highly connected to the expression of immunological checkpoints, immune cell biomarkers, and tumor immune cell invasion. Conclusions: Our findings reveal that PIK3CD expression is associated with prognosis, EMT, and tumor immune infiltration in BRCA patients.
- Open Access
- 18 May 2022
- Published by Elsevier in Biochemistry and Biophysics Reports
- Vol. 30, 101279
LncRNA HOTAIR promotes the proliferation and invasion/metastasis of breast cancer cells by targeting the miR-130a-3p/Suv39H1 axis
- 18 May 2022
- Published by Elsevier in Biochemistry and Biophysics Reports
- Vol. 30, 101279
Open AccessLncRNA HOTAIR promotes the proliferation and invasion/metastasis of breast cancer cells by targeting the miR-130a-3p/Suv39H1 axis